Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up (ASH 2019) - Nov 7, 2019 - Abstract #1538; Pres time: Dec 7, 2019; 05:30 PM - 07:30 PM; Location: Hall B, Level 2 (Orange County Convention Center); P2, P3, P3b; "Methods Patients (pts) enrolled in SPARK (MCL2001; NCT01599949), RAY (MCL3001; NCT01646021), and PCYC-1104 (NCT01236391) received ibrutinib 560 mg orally once daily until progressive disease or unacceptable toxicity, and pts benefiting at end of study could enroll in the open-label long-term extension study CAN3001 (NCT01804686). In chemosensitive pts with late frontline POD, second-line ibrutinib PFS was 36% longer than frontline outcome. There was no notable emerging toxicity with additional follow-up."
Retrospective data • TP53
|
|
Simon Rule1; Martin H. Dreyling, MD, PhD2; Andre Goy, MD3; Georg Hess4; Rebecca Auer, MRCP, FRPath, PhD5; Brad S. Kahl, MD6; Jose Angel Hernandez-Rivas, MD, PhD7; Keqin Qi, PhD8; Sanjay Deshpande9; Lori Parisi9; Michael L. Wang, MD10
|